Psoriasis Awareness Month
August is Psoriasis Awareness Month which aims to help affected people feel supported, raise awareness and give the public a better understanding of the disease. Psoriasis Australia
UpToDate
Diagnosis
General
Treatment
Cochrane Library
Articles
Diagnosis
Research
Treatment
E-books
E-journals
__________________________________________________________________________________
Articles
Diagnosis
Oxidative stress and metabolic biomarkers in patients with psoriasis
Multimarker approach showed that metabolic and renal function related factor and oxidative stress-hepatic related factor were better predictors of psoriasis severity than each single examined biomarker. Journal of medical biochemistry 1 August 2023
Understanding discordant perceptions of disease severity between physicians and patients with Eczema and Psoriasis using structural equation modelling
This cross-sectional study identified various modifiable contributory factors to discordant severity grading (DSG), increased understanding of the phenomenon, and set a framework for targeted interventions to bridge this discordance. JAMA 12 July 2023
Are quantitative histopathologic criteria capable of differentiating psoriasis from chronic dermatitis?
Despite overlapping histopathologic features in psoriasis and chronic dermatitis, quantitative histopathologic criteria might be valuable for differentiation of these two conditions. Ratios of minimal suprapapillary plate’s thickness to epidermal thickness and minimal granular layer’s thickness to parakeratotic layer’s thickness can be particularly helpful in this regard. Clinical, cosmetic and investigational dermatology 18 December 2022
Inverse Psoriasis: From diagnosis to current treatment options
Inverse psoriasis represents a clinical variant of psoriasis that is sometimes difficult to diagnose due to its clinical similarity with other skin disorders involving the folds, mainly including mechanical intertrigo, fungal and bacterial infections, contact dermatitis, seborrheic dermatitis, and lichen planus. Dermoscopy represents a useful tool for an enhanced non-invasive diagnosis. The treatment of inverse psoriasis may be challenging and include topical corticosteroids, topical calcineurin inhibitors, vitamin D analogs, traditional oral systemic therapies such as cyclosporine and methotrexate, and biologic therapies. Clinical, cosmetic and investigational dermatology 13 November 2022
Transcriptome analysis identifies Biomarkers for the diagnosis and management of Psoriasis complicated with depression
study reveals the common pathogenesis of psoriasis and depression. These common pathways and hub genes may apply to a molecular screening tool for depression in psoriasis patients, which could help dermatologists optimize patient management in routine care. Clinical, cosmetic and investigational dermatology 17 May 2023
Psoriasis seems often underdiagnosed in patient with axial spondyloarthritis
Especially mild psoriasis seems often underdiagnosed in patients with axSpA using a patient questionnaire with prototypical pictures of psoriasis lesions. This questionnaire could be beneficial in tracing patients with undiagnosed psoriasis in daily clinical practice. As a next step, further validation of this questionnaire is needed. Arthritis research & therapy 9 August 2023
__________________________________________________________________________________
Research
Using the patient-acceptable symptom state to evaluate patients' perspectives of living with psoriasis: A cross-sectional study
Patient-acceptable symptom state (PASS) is a simple and easily administered questionnaire that reflects both disease severity and HRQoL. Understanding patients' needs and satisfaction levels will result in better care for psoriatic patients than otherwise. Australasian journal of dermatology 20 December 2021
National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study
Eighty one per cent of the countries of the world lack information on the epidemiology of psoriasis. The disease occurs more frequently in adults than in children. Psoriasis is unequally distributed across geographical regions; it is more frequent in high income countries and in regions with older populations. The estimates provided can help guide countries and the international community when making public health decisions on the appropriate management of psoriasis and assessing its natural history over time. BMJ 28 May 2020
Association between Psoriasis and Non-alcoholic Fatty Liver Disease among outpatient US adults
n this cross-sectional study, psoriasis was associated with NAFLD in the outpatient US adult population in adjusted models. This association may be important to consider in the context of clinicians prescribing potentially hepatotoxic medication for psoriasis management. JAMA 25 May 2023
Increased risk of psoriasis: An immune sequela of herpes zoster? Evidence from a nationwide population-based cohort study
This study demonstrated an increased risk of psoriasis in patients diagnosed with herpes zoster. Australasian journal of dermatology 4 November 2022
A cross-sectional study of depression and quality of life in psoriasis
These results accord with previous studies indicating significant risk of depression in psoriasis patients. Screening for depression should form an important part of clinical assessment. More research will be required to establish the impacts of psychiatric treatment on clinical status, functional capacity and quality of life in patients with psoriasis. Australasian journal of dermatology 12 July 2021
Injections site reactions and Biologics for Psoriasis: A questionnaire based real life study
This study highlighted that each different class of biologics for psoriasis was linked to injection site reactions (ISRs). These events are more frequently reported with anti-TNF-alpha and anti-IL17. Clinical, cosmetic and investigational dermatology 2 March 2023
__________________________________________________________________________________
Treatment
Australian consensus: Treatment goals for moderate to severe psoriasis in the era of targeted therapies – Adult patients
The ability of new targeted treatment options to change the narrative in psoriasis patient care can only be properly realised if challenges to timely and equitable access are addressed. The proposed framework for the assessment, classification and management of moderate–severe psoriasis aligns with international recommendations. Its adoption into Australian clinical practice is hoped to improve treatment outcomes and patients' satisfaction with their care. The Australian journal of dermatology 28 July 2023
Secukinumab treatment showed improved quality of life in patients with chronic plaque psoriasis in Australia: Results from the HOPE study
Secukinumab treatment demonstrated a striking improvement in patients' QoL in the HOPE study, the first real-world study in patients with severe chronic plaque psoriasis in the Australian clinical setting. The Australian journal of dermatology 11 July 2022
Secukinumab treatment demonstrated high drug survival and sustained effectiveness in patients with severe chronic plaque psoriasis: 21-month analysis in Australian routine clinical practice (SUSTAIN study)
Secukinumab demonstrated high drug survival and sustained effectiveness in Australian real-world setting, in biologic-naïve and biologic-experienced patients with severe CPP. The Australian journal of dermatology 9 July 2022
International eDelphi study to reach consensus on the Methotrexate Dosing Regimen in patients with Psoriasis
The findings of this study suggest that this consensus can be used in guideline documents as well as further optimization of methotrexate treatment in patients with psoriasis. JAMA 30 March 2022
Patient-relevant outcomes in Psoriasis: A systematic review
This systematic review examined which outcomes were relevant to patients when managing their psoriasis; incorporating these in the clinical care path may aid the transition to a value-based treatment approach. JAMA 8 June 2023
Matching-adjusted indirect comparison of the long-term efficacy of Deucravacitinib versus Adalimumab for moderate to severe Plaque Psoriasis
In this interim analysis, adults with moderate to severe PsO had higher long-term response rates at 2 years when treated with deucravacitinib versus adalimumab. Deucravacitinib response rates remained stable whereas adalimumab response rates declined in year 2. Dermatology and therapy 31 July 2023
Brodalumab in the treatment of Plaque Psoriasis localized in difficult-to-treat areas: A narrative review
Brodalumab, combining rapid and sustained efficacy with a favorable safety profile, may be a valid therapeutic option for severe variants of psoriasis as well as for psoriasis localized in difficult-to-treat areas. Dermatology practical and conceptual 25 July 2023
Trial of Spesolimab for generalized Pustular Psoriasis
In a phase 2 randomized trial involving patients with GPP, the interleukin-36 receptor inhibitor spesolimab resulted in a higher incidence of lesion clearance at 1 week than placebo but was associated with infections and systemic drug reactions. Longer and larger trials are warranted to determine the effect and risks of spesolimab in patients with pustular psoriasis. NEJM 23 December 2021
Phase 3 trials of Tapinarof cream for Plaque Psoriasis
Tapinarof 1% cream once daily was superior to vehicle control in reducing the severity of plaque psoriasis over a period of 12 weeks but was associated with local adverse events and headache. Larger and longer trials are needed to evaluate the efficacy and safety of tapinarof cream as compared with existing treatments for psoriasis. NEJM 9 December 2021
Bimekizumab versus Adalimumab in Plaque Psoriasis
In this 56-week trial, bimekizumab was noninferior and superior to adalimumab through 16 weeks in reducing symptoms and signs of plaque psoriasis but was associated with a higher frequency of oral candidiasis and diarrhea. Longer and larger trials are required to determine the efficacy and safety of bimekizumab as compared with other agents in the treatment of plaque psoriasis. NEJM 8 July 2021
Bimekizumab versus Secukinumab in Plaque Psoriasis
In patients with moderate-to-severe psoriasis, treatment with bimekizumab resulted in greater skin clearance than treatment with secukinumab over 16 and 48 weeks but was associated with oral candidiasis (predominantly mild or moderate as recorded by the investigator). Longer and larger trials are required to determine the comparative effect and risks of interleukin-17 inhibitors in psoriasis. NEJM 8 July 2021
Successful management of treatment resistant nail psoriasis with tildrakizumab
Nail psoriasis significantly impacts quality of life and is notoriously difficult to treat. Tildrakizumab, an IL-23 inhibitor, has shown significant clinical improvement in the treatment of moderate-to-severe chronic plaque psoriasis. The Australian journal of dermatology 11 June 2021
Nail Psoriasis: An updated review of currently available systemic treatments
Several therapies have demonstrated efficacy and safety in the treatment of NP; however, the choice of treatment depends not only on the severity of the nail involvement, but also on whether PsA is present, the patient’s comorbidities other than PsA, previous treatment history, and the patient’s drug preferences. Clinical, cosmetic and investigational dermatology 24 July 2023
_________________________________________________________________________________
This is just a sample of the e-books the library subscribes to – you will need your library login
__________________________________________________________________________________
This is just a sample of the journals the library subscribes to – you will need your library login
